Edgewise Therapeutics Inc at Cowen Health Care Conference Transcript
Today, we have Edgewise Therapeutics for a featured presentation. From the company we have the company's CEO, Kevin Koch, for the presentation today. The floor is yours.
Thank you. Well, thank you all for coming today and look forward to giving you this update with regards to the company. I'll get situated here. Okay.
This is my disclaimer for some of the things I'll be saying today. So Edgewise as a company with a very strong management team -- years of industry experience from companies like Edgewise, Array, Amgen, Genzyme -- many years of experience developing drugs to treat devastating muscle disorders. All of our targets come from our own internal discovery efforts. They are all novel. These are not best-in-class drugs, these are novel targets, trying to go after these very difficult-to-treat muscle diseases.
Our first target and first drug, Edgewise 5506, we believe could become a foundational medicine for the treatment of a broad range of muscular dystrophies
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |